Ifosfamide for Injection

DRUG2 trials

Sponsors

BeBetter Med Inc

Conditions

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-12-01End: 2025-11-05Target: 75Updated: 2023-12-11

Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT06792253

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2025-01-06End: 2029-06-30Target: 416Updated: 2025-01-24

Related Papers

Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.

Journal of Clinical Oncology2025-05-281 citations